GCM
AZN icon

Grisanti Capital Management’s AstraZeneca AZN Stock Holding History

Grisanti Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-19,400
Closed -$1.26M – 61
2014
Q1 		$1.26M Sell
19,400
-30
-0.2% -$1.94K 0.55% 29
2013
Q4 		$1.15M Buy
19,430
+6,660
+52% +$362K 0.5% 31
2013
Q3 		$663K Buy
+12,770
New +$641K 0.31% 36

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Grisanti Capital Management's AZN Position: Q2 2014 in Review

Grisanti Capital Management sold out of AstraZeneca (AZN) in Q2 2014, closing a stake of 19,400 shares — an estimated $1.26M sold.

Grisanti Capital Management first reported a position in AZN in Q3 2013 and held it in 3 quarters. The position peaked at $1.26M in Q1 2014. 418 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

  • Grisanti Capital Management reported no remaining AstraZeneca position as of Q2 2014 after selling out during the quarter.
  • Grisanti Capital Management sold 19,400 AstraZeneca shares in Q2 2014, an estimated $1.26M.
  • Grisanti Capital Management first reported a position in AstraZeneca in Q3 2013 and held it in 3 quarters.
  • Grisanti Capital Management's AstraZeneca position peaked at $1.26M in Q1 2014.
  • 418 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on Grisanti Capital Management's 13F filing for Q2 2014, filed 6 Aug 2014.